|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reveal that NORAD/miR-608/STAT3 axis is pivotal in mediating the antineoplastic impacts of PG on ovarian cancer cells, which may offer a novel explanation in the therapy of ovarian cancer.
|
31299866 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study proved for the first time that miR-519a functions as a tumor suppressor by targeting STAT3 in ovarian cancer, suggesting that miR-519a may be a potential biomarker for the diagnosis and treatment of ovarian cancer.
|
29434770 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intriguingly, we demonstrated that M-MDSC could be readily induced by ascitic fluids (AF) from OC patients, which was predominantly dependent on IL-6, IL-10 and STAT3 activation as neutralization of IL-6 and/or IL-10 or inhibition of STAT3 abrogated MDSC's expansion while recombinant IL-6 and IL-10 recapitulated the expansive effect of AF; furthermore, predominantly elevated levels of IL-6 and IL-10 has been noted in the AF which was positively correlated with the abundance of M-MDSC as well as poor prognosis of OC patients.
|
29100353 |
2017 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, these compounds may serve as candidate compounds for further modification and development as anticancer therapeutics targeting the DBD of human STAT3 for treatment of cisplatin-resistant ovarian cancer.
|
30145375 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation and translocation of pStat3 to the nucleus are frequent events in ovarian carcinoma that are associated with a poor prognosis.
|
17063503 |
2006 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
|
30622051 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin (IL)-6 and Stat3 play key roles in ovarian cancer progression.
|
23536726 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Signal transducer and activator of transcription 3 (STAT3) is activated in majority of ovarian tumors and confers resistance to cisplatin treatment in patients with ovarian cancer.
|
22280969 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results offer preclinical proof-of-concept for HO-3867 as a selective STAT3 inhibitor to treat ovarian cancer and other solid tumors where STAT3 is widely upregulated.
|
24590057 |
2014 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
|
28209618 |
2017 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that a combined approach of targeting high-invasive OVCA cells by blocking glutamine's entry into the TCA cycle, along with targeting low-invasive OVCA cells by inhibiting glutamine synthesis and STAT3 may lead to potential therapeutic approaches for treating OVCAs.
|
24799285 |
2014 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, phosphorylated-Stat3 (Tyr705) amounts OC cell invasion and migration, and expression of matrix metalloproteinases (MMP-9 and MMP-2) decreased.
|
30182276 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate whether the STAT3 inhibitor HO-3867, a novel curcumin analog, has a therapeutic effect on BRCA1-mutated ovarian cancer.
|
22801507 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
STAT3 regulated <i>miR-216a</i> promotes ovarian cancer proliferation and cisplatin resistance.
|
30061175 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the IL-6-Stat3 pathway contributes to tumor cell growth, survival and drug resistance in several cancers, including ovarian cancer.
|
18587580 |
2009 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer.
|
28188387 |
2017 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results revealed that the STAT3 decoy ODN inhibited ovarian cancer cell growth and promoted ovarian cancer cell apoptosis in vivo.
|
23828376 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Less is known about the role of LIF, which can similarly activate STAT3, in ovarian cancer.
|
30305729 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
|
29930760 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.
|
27590741 |
2016 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.
|
28983974 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation of JAK2/STAT3 pathway had significant impact on survival of ovarian cancers, especially for the cases with clear-cell histology.
|
29545902 |
2018 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway.
|
31477564 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer.
|
21909139 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the formation of many tumors including ovarian cancer.
|
18535750 |
2008 |